Copley Pharmaceuticals
Executive Summary
Generic drug firm expects to commence 1.9 mil. share initial public offering in mid-October. In an amended registration statement filed Sept. 14, Copley raised the estimated price-per-share from $14-$16 to $17-$19. The preliminary prospectus was filed April 24 ("The Pink Sheet" May 25, p. 7). Proceeds are estimated at $30.8 mil., based on $18 per share price. Copley has received 12 ANDA approvals in 1992, and a total of 38 ANDAs to date. The firm has had a total of 11 first ANDAs, of which seven are still the exclusive generic product approval. Copley holds the second tentative ANDA approval for Marion Merrell Dow's Cardizem (diltiazem), not Lederle ("The Pink Sheet" Sept. 7, T&G-2). Lederle's tentative approval was third chronologically.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth